Skip to content

Fractional Laser Versus Radiofrequency in Androgenetic Alopecia

Fractional Microneedling Radiofrequency Versus Fractional Carbon Dioxide Laser in Combination With Minoxidil for the Treatment of Androgenetic Alopecia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05435625
Enrollment
30
Registered
2022-06-28
Start date
2022-01-01
Completion date
2022-12-01
Last updated
2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic Alopecia

Brief summary

Patients with Androgenetic alopecia will be randomized into 2 groups; Group FCO2 receiving Fractional CO2 or Group FRF receiving Fractional Microneedling Radiofrequency.

Detailed description

Group FCO2 will be to receiving fractional CO2 to one randomized side of the scalp, and Group FRF will be receiving Fractional Microneedling radiofrequency to one randomized side of the scalp. All patients will receive 4 sessions with 4-week intervals.each session will be followed by immediate topical application of 6 puffs (=1 mL) of minoxidil 5% solution twice daily and also in between the sessions and during follow up period

Interventions

PROCEDUREFCO2

Fractional Carbon dioxide laser

PROCEDUREFRF

Fractional Microneedling Radiofrequency

Sponsors

Kasr El Aini Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* • both genders are included. * Patients above 18 years old.

Exclusion criteria

* • Patients with patchy hair loss. * Patients with Telogen Effluvium or diffuse alopecia areata. * Patients with cicatricial alopecias. * Patients with associated inflammatory scalp disorders such as psoriasis or seborrheic dermatitis. * Patients with collagen vascular disorders. * Prior use of topical steroids on scalp in the previous 2 weeks. * Prior use of systemic steroids in the previous 1 month.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Global improvement Assessment6months-1 yearPhotographs will be taken with a Canon camera under controlled light in approximately the same position, taken at baseline, after 4 treatment sessions (16 weeks post treatment) and 2 months after follow-up (24 weeks post treatment). First clinical assessment will be performed based on the clinical change from baseline at 16 weeks post treatment. Change in the clinical will be measured on a 6 point scale; (-1) worsening, (0) no improvement, (1) less than 25% improvement, (2) 25-50% improvement, (3) 50-75% improvement, (4) more than 75% improvement. A higher numerical means a better outcome.
Phototrichogram assessment.months-1 yearA phototrichogram system (Dino-Lite; AnMo Electronics, Taiwan)will be used to evaluate the number of hairs. A higher numerical means a better outcome.
Patient satisfaction6months-1 yearParticipants will be also asked to give their assessment on a scale of 4, (0) no satisfaction (1) slight satisfation, (2) moderate satisfaction, (3) marked satisfaction. A higher numerical means a better outcome.

Countries

Egypt

Contacts

Primary ContactRana Hilal, MD
rana.hilal@kasralainy.edu.eg2010014888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026